MGS, a global healthcare contract development and manufacturing organization (CDMO), has expanded its hybrid tooling capabilities worldwide, strengthening its ability to help pharmaceutical, diagnostics and medical technology companies accelerate product development while reducing manufacturing risk. The expanded offering builds on the successful deployment of the company’s A.i.r. Platform™ and is designed to support customers from early product design through commercial manufacturing.
The enhanced hybrid tooling solution provides healthcare manufacturers with an efficient pathway between prototype development and full-scale production. By enabling the creation of injection-molded components under manufacturing-representative conditions before investing in final production tooling, the approach allows companies to validate product designs earlier while maintaining shorter development timelines.
Unlike conventional prototype tooling methods that rely primarily on 3D printing or aluminum molds, the hybrid tooling system combines aluminum tooling with strategically placed steel inserts in areas requiring high precision, durability and material consistency. This design enables manufacturers to closely replicate production conditions, providing valuable insights into tooling performance, material behavior and manufacturability without the cost and lead time associated with permanent production tools.
The approach offers healthcare companies greater confidence during product development by identifying potential manufacturing challenges before large-scale production begins. It also supports smoother technology transfer and reduces the likelihood of costly redesigns later in the product lifecycle.
According to Shawn Krenke, Chief Technology Officer at MGS, healthcare manufacturers face increasing pressure to shorten development cycles while minimizing technical and commercial risks. He said the expanded global availability of hybrid tooling enables customers to validate critical design decisions under production-like conditions without committing to full production tooling at an early stage, helping accelerate innovation with greater confidence.
The hybrid tooling platform can deliver production-representative molded components in as little as one month, allowing development teams to evaluate product performance earlier in the design process. The capability supports faster product development, improves design validation, identifies manufacturing considerations before commercialization, minimizes downstream production risks and enables a more efficient transition into scalable manufacturing. As healthcare companies continue to introduce increasingly sophisticated medical devices and drug delivery systems, rapid product validation has become a key factor in reducing time to market while maintaining stringent quality standards.
MGS provides end-to-end contract development and manufacturing services to leading pharmaceutical, diagnostics and MedTech companies worldwide. By combining engineering expertise, advanced manufacturing technologies and collaborative product development, the company supports customers throughout the product lifecycle, from concept development and design validation to large-scale commercial production. The global expansion of hybrid tooling further reinforces MGS’ commitment to providing innovative manufacturing solutions that help healthcare companies accelerate product development, improve production readiness and bring new medical technologies to patients more efficiently.
